Bioventus Financials - Benzinga

Bioventus Inc

BVSNASDAQ

Trade with Public

Trade with Public

$12.91

0.282.22%

At close: Sep 17, 5:00 PM EST

$12.90

0.272.14%

Pre-Market: 5:44 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Bioventus Financials

Bioventus (BVS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Bioventus Q2 Adj. EPS $0.22, Inline, Sales $153.208M Miss $155.640M Estimate

Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.22 per share which met the analyst consensus estimate. This is a 4.76 percent increase over earnings of $0.21 per share from the same period last year. The

Benzinga Newsdesk

PRO
Bioventus Affirms FY2026 Adj EPS Guidance of $0.75-$0.79 vs $0.78 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $605.756M Est

Bioventus (NASDAQ:BVS) affirms FY2026 Adj EPS guidance from $0.75-$0.79 to $0.75-$0.79 vs $0.78 analyst estimate. Affirms FY2026 sales outlook from $600.000 million-$610.000 million to $600.000 million-$610.000 million

Benzinga Newsdesk

PRO
Bioventus Says FDA Reclassifies Exogen Ultrasound Bone Healing System To Class II Device On April 16, 2026; CMS Updates Medicare Fee Schedule For Non-Invasive Bone Growth Stimulators Effective May 18, 2026; Does Not Expect Material Impact From Exogen Reimbursement Changes In FY26; Reiterates 2026 Financial Guidance - SEC Filing

On April 16, 2026, the U.S. Food and Drug Administration ("FDA") issued a final order reclassifying non-invasive bone growth stimulators, including the Company's Exogen® Ultrasound Bone Healing System, from Class

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Bioventus Raises FY2026 Adj EPS Guidance from $0.73-$0.77 to $0.75-$0.79 vs $0.75 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $604.747M Est

Bioventus (NASDAQ:BVS) raises FY2026 Adj EPS guidance from $0.73-$0.77 to $0.75-$0.79 vs $0.75 analyst estimate. Affirms FY2026 sales outlook from $600.000 million-$610.000 million to $600.000 million-$610.000 million vs

Benzinga Newsdesk

PRO
Bioventus Q1 Adj. EPS $0.15 Beats $0.10 Estimate, Sales $132.089M Beat $129.850M Estimate

Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.10 by 50 percent. This is a 87.5 percent increase over earnings of $0.08 per share from the same

Benzinga Newsdesk